Cargando…
Key questions about the checkpoint blockade-are microRNAs an answer?
The introduction of immune-checkpoint blockade in the cancer therapy led to a paradigm change of the management of late stage cancers. There are already multiple FDA approved checkpoint inhibitors and many other agents are undergoing phase 2 and early phase 3 clinical trials. The therapeutic indicat...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Chinese Anti-Cancer Association
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994554/ https://www.ncbi.nlm.nih.gov/pubmed/29951335 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0006 |